thalidomide has been researched along with Necrobiotic Xanthogranuloma in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Necrobiotic Xanthogranuloma: A cutaneous necrobiotic disorder characterized by firm, yellow plaques or nodules, often in a periorbital distribution. It is often accompanied by an elevated ERYTHROCYTE SEDIMENTATION RATE; LEUKOPENIA; and MONOCLONAL GAMMOPATHY (IgG-kappa type) and systemic involvement.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Necrobiotic xanthogranuloma is a rare chronic condition, belonging to the group C non-Langerhans cell histiocytoses, which is relevant due to the possibility of extracutaneous involvement and association with systemic diseases, particularly hematologic malignancies." | 5.51 | Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide. ( Mello, RB; Vale, ECSD, 2019) |
| "Necrobiotic xanthogranuloma is a rare chronic condition, belonging to the group C non-Langerhans cell histiocytoses, which is relevant due to the possibility of extracutaneous involvement and association with systemic diseases, particularly hematologic malignancies." | 1.51 | Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide. ( Mello, RB; Vale, ECSD, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, FR | 1 |
| Lear, JT | 1 |
| Mahendran, P | 1 |
| Wee, J | 1 |
| Chong, H | 1 |
| Natkunarajah, J | 1 |
| Mello, RB | 1 |
| Vale, ECSD | 1 |
| Ghani, S | 1 |
| Al Ustwani, O | 1 |
| Khalid, B | 1 |
| Bogner, P | 1 |
| Grassi, M | 1 |
| Powell, J | 1 |
| Bhat, SA | 1 |
| Dholaria, BR | 1 |
| Cappel, M | 1 |
| Roy, V | 1 |
| Efebera, Y | 1 |
| Blanchard, E | 1 |
| Allam, C | 1 |
| Han, A | 1 |
| Lee, S | 1 |
| Munshi, N | 1 |
1 review available for thalidomide and Necrobiotic Xanthogranuloma
| Article | Year |
|---|---|
Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature.
Topics: Aged; Dexamethasone; Humans; Immunosuppressive Agents; Male; Necrobiotic Xanthogranuloma; Paraprotei | 2011 |
5 other studies available for thalidomide and Necrobiotic Xanthogranuloma
| Article | Year |
|---|---|
Thalidomide for necrobiotic xanthogranuloma.
Topics: Dexamethasone; Humans; Necrobiotic Xanthogranuloma; Thalidomide | 2022 |
Necrobiotic xanthogranuloma treated with lenalidomide.
Topics: Aged; Angiogenesis Inhibitors; Dermatologic Agents; Female; Humans; Immunologic Factors; Lenalidomid | 2018 |
Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide.
Topics: Cyclophosphamide; Dexamethasone; Female; Humans; Immunosuppressive Agents; Middle Aged; Necrobiotic | 2019 |
Periorbital necrobiotic xanthogranuloma treated successfully with novel multiple myeloma therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Female; Humans; Lenalidomid | 2013 |
Necrobiotic xanthogranuloma associated with monoclonal gammopathy: successful treatment with lenalidomide and dexamethasone.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Drug Therapy, Combination; | 2016 |